trending Market Intelligence /marketintelligence/en/news-insights/trending/KcHbSpFZ-QWKuFngqYiu3A2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Omeros raises $57.5M from stock offering

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Omeros raises $57.5M from stock offering

Omeros Corp. said it raised $57.5 million after underwriters of its previously announced offering fully exercised their overallotment option.

The Seattle-based pharmaceutical company sold 4,389,311 shares at $13.10 apiece, including the additional 572,518 shares as part of underwriters' overallotment option.

Cantor Fitzgerald & Co. acted as the sole book-running manager for the offering, which closed Dec. 9.

Omeros hopes to use the net proceeds for general corporate purposes, capital expenditures and to fund its products' clinical and preclinical trials.

Earlier this year, a European Medicines Agency committee backed Omeros' OMS721 for the treatment of a life-threatening complication of stem cell transplant called hematopoietic stem cell transplant-associated thrombotic microangiopathy.

The company is also seeking U.S. approval of the drug.